Members' News

28th Nov 2017

NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award

 NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award

Full Story

11th Nov 2017

Successful year of growth for Sitekit

by Madelon Kortenaar

Full Story

31st Oct 2017

Capsugel Announces Expanded Capabilities for Clinical Trial Services at Edinburgh Facility

 

Full Story

4th Oct 2017

Sistemic announce significant progress of pluripotent stem cell contamination in derived CT products

 Sistemic announce significant progress of pluripotent stem cell contamination technology in derived cell therapy products

Full Story

28th Sep 2017

Eurofins Increases Capacity and Strengthens Capability at New Facility

                                                 

Full Story

27th Sep 2017

NuCana plc Announces Pricing of Initial Public Offering

NuCana plc Announces Pricing of Initial Public Offering.

Full Story

25th Sep 2017

Life Sciences Scotland Strategy: Conference, 21st November - SPECIAL RATE FOR SLA MEMBERS

 

Full Story

15th Sep 2017

TGaS Advisors Teams with Mirador Analytics to Improve Forecasting to Biopharmaceutical Environment

/Click here to read full Press Release

Full Story

10th Sep 2017

Contacts In Science - Women Returning to Life Sciences

  

Full Story

29th Aug 2017

Aridhia and Great Ormond Street Hospital Sign Ten-Year Research and Innovation Platform Deal

 Aridhia, the cloud-based data analysis platform provider, has agreed a new ten-year deal with Great Ormond Street Hospital NHS Foundation Trust (GOSH) which will see it deliver the research and innovation component of the Trust’s multi-year digital transformation programme.

Full Story

21st Jul 2017

Cyclacel Announces Closing of $15.2 Million

Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) --

Full Story

7th Jul 2017

Collagen Solutions Announces First Patient Enrolment in ChondroMimetic Clinical Study

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the commencement of patient enrolment into an open label extension study as part of the clinical development programme for ChondroMimetic®, an osteochondral scaffold for the repair of cartilage defects in the knee. CE-marking for ChondroMimetic® was previously achieved prior to the Company’s acquisition of the product and related IP, and this follow-up clinical study is a step towards reestablishing that CE-mark certification.

Full Story

3rd Jul 2017

Ryboquin Secures 1.8m Equity Funding

Ryboquin Secures £1.8m Equity Funding

Full Story

22nd Jun 2017

Sistemic Ltd Announce Innovate UK Grant to Develop Grounbreaking miRNA-based Assay

Sistemic awarded an Innovate UK grant to develop a groundbreaking, novel miRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products Glasgow, Scotland, 22th June 2017 Sistemic Ltd announced today the award of an Innovate UK grant to further develop, to a market-ready stage, its groundbreaking prototype microRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products. Sistemic will be partnered in this project by LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement. Cell therapies are seen as the future of treatment in a number of therapeutic areas including diabetes and cardiovascular disease and are expected to revolutionise medical care for a range of currently untreatable diseases. Cell therapies are increasingly using pluripotent stem cells (PSCs) to generate derived cell therapy products. However, PSCs, by their nature, have the potential to form tumours which raises concerns around PSC-derived cell product safety. Therefore, there is a need to demonstrate, sensitively, quickly and accurately, the level of contaminating pluripotent stem cells in a derived cell therapy product. Sistemic has developed a prototype product based around miRNA biomarkers to detect contaminating pluripotent stem cells in a derived cell therapy product in a simple, highly sensitive and rapid test format. This partnership will support Sistemic in order to further develop their prototype product and make it ready for the rapidly developing market in PSC-derived cell therapy products Sistemic will be supported by the UK’s innovation agency, Innovate UK, under “The Analysis for Innovators” grant.

Full Story

13th Jun 2017

Collagen Solutions - Provisional Patent for Bone Graft Substitute Formulation Submitted

 

Full Story

8th May 2017

Lamellar Biomedical Raises 5.75m in Series C Fund Raising Led by Invesco

Lamellar Biomedical Raises £5.75 million in Series C Fund Raising Led by Invesco

Full Story

4th May 2017

Sartorius Stedim Biotech Launches Chemistry Testing Services

 

Full Story

28th Apr 2017

SBRI Funding Competition: Clinical Decision Support In Emergency Care

SBRI funding competition: clinical decision support in emergency care From:Innovate UKPart of:Innovation grants for business: apply for funding, Business enterprise, and Research and innovation in health and social careFirst published:3 April 2017Last updated:10 April 2017, see all updates  

Full Story

27th Apr 2017

Dundee Cell Products Ltd. Rebrands as DC BIOSCIENCES Ltd

Please click here for the full press release

Full Story

25th Apr 2017

Medical Research Scotland PhD Studentships - Call Open

MEDICAL RESEARCH SCOTLAND

Full Story

19th Apr 2017

Synpromics Raises 5.2m of New Investment

Edinburgh, UK, 19th April 2017 / Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M.

Full Story

6th Apr 2017

MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3

 MGB Biopharma Closes $1 million Financing Round to Finance Manufacturing of MGB-BP-3 for Phase II Study in Clostridium difficile-Associated Disease (CDAD)

Full Story

23rd Mar 2017

Opportunity to Hear David Evans Present 'A Chairman's Story' at UK Investor Show

 23 March 2017

Full Story

14th Mar 2017

Mirador Analytics Launches Online Version of Asset Evaluation Tool

Revolutionizing Asset Evaluation for Drug Development and Commercialization

Full Story

22nd Feb 2017

Aridhia Wins 10-Year Deal with Great Ormond Street Hospital

Click here for full Press Release

Full Story

15th Feb 2017

Collagen Solutions to Raise 12 million

SLA Member Collagen Solutions in £12m growth plan, see the press releases below for details:

Full Story

1st Feb 2017

OncoBioPharm rebrands as 'aTen Therapeutics'

1 February 2017   OncoBioPharm Ltd is rebranded as aTen Therapeutics Ltd   Scottish biotechnology company OncoBioPharm has announced that from today it will operate as aTen Therapeutics Ltd. aTen (pronounced ‘atten’) refers to the angiotensin pathway, which plays a key role in several major diseases, and is the target of the company’s lead antibody candidate, Tensinomab. The new name reflects the company’s commitment to exploring the full potential of its innovative technology platform, not only within oncology but across other major disease areas.   Click here to read more

Full Story

16th Jan 2017

NovaBiotics Announces First Patients Dosed in Lynovex Clinical Study

 NovaBiotics announces first patients dosed in Lynovex clinical study

Full Story

19th Dec 2016

SLA welcomes the 30% increase in revenues at Collagen Solutions

Collagen Solutions Plc - (the "Company" or the “Group”). Half Year Report : Interim Results for the six months ended 30 September 2016

Full Story

6th Dec 2016

Lamellar Biomedical Completes Patient Recruitment for Clinical Study Assessing Visco-ease

Lamellar Biomedical Announces Completion of Patient Recruitment in the Pivotal Registration Clinical Study Assessing Visco-ease for the Treatment of Radiotherapy-Induced Xerostomia (RIX)

Full Story

16th Nov 2016

DataVita Announces GxP Compliant Datacentre Hosting for Lifescience & Healthcare Sectors

DataVita, Scotland’s premier datacentre provider, has announced this week that the Fortis datacentre is now GxP compliant, creating a specialist offering for Life Science, Biotech and Healthcare organisations. It has selected CompliancePath, a specialist GxP consultancy, to deliver the compliance and validation services.

Full Story

1st Nov 2016

Scottish biotechnology companies to chair expert panel session at Pharma Integrates

Dr Tina Flatau, Managing Director of innovative Edinburgh-based biotechnology companies OncoBioPharm Ltd and MedAnnex Ltd, has been invited to chair a panel session of experts at the 2016 Pharma Integrates conference at London’s Grange City Hotel later this month.  Please click this link for the full press release.   

Full Story

8th Sep 2016

Arrayjet Secures £650k Funding to Accelerate Innovation

Click here to read articles regarding SLA member Arrayjet's record fumding round:

Full Story

31st Aug 2016

SLA Response to Scottish Government Enterprise & Skills Review

Please click here to read the response from SLA to the SG Enterprise and Skills Review

Full Story

22nd Aug 2016

Aridhia's Data & Analytics Service Selected For Use In Landmark £6.9M Alzheimer's Study

Scottish informatics company Aridhia will be among a cohort of research organisations undertaking the world’s most in-depth study to better detect Alzheimer’s Dementia, aiming to identify early signs of the disease and improve our understanding of its progression.

Full Story

22nd Aug 2016

Matthew Speers new CEO of the Life Sciences Organisation (LSO)

The Department for International Trade’s (DIT) Life Sciences Organisation (LSO) is pleased to confirm Matthew Speers as our new CEO, effective 22nd August 2016.  Matthew will take over from Dr Mark Treherne who has led the organisation since 2012 helping, along with others, to attract more than 6 billion pounds in new investment and create more than 17,000 new jobs in the sector.

Full Story

18th Aug 2016

Edinburgh Napier Applied Science Graduate Careers Festival

Calling all Life, Sport and Social Science employers!

Full Story

15th Aug 2016

NSF Medical Devices Training Courses - Discount for SLA Members

www.nsf.org/training-education/all-courses/category/training-medical-devices   NSF Health Sciences would like to offer SLA members a 40% discount for each delegate reserving a place on any of their courses. The offer is limited to the first 10 places on a first come, first served basis and will only be valid until 26 August 2016.   If you or any of your members wish to learn more about the content of the courses, please speak directly to the tutor, James Pink. James may be contacted on +44 (0) 7850 900679 or by email at  jamespink@nsf.org    

Full Story

5th Aug 2016

NovaBiotics Commercial Collaboration Deal for (Oral) Lynovex®

NovaBiotics Ltd, the UK-based clinical-stage anti-infectives biotechnology company, today announced that it has entered into an agreement with an undisclosed global partner to commercialise Lynovex®, the Company’s first-in-class oral intervention for acute infectious exacerbations associated with cystic fibrosis (“CF”).  

Full Story

2nd Aug 2016

Omega Diagnostics Secures £1.8m R&D Grant

Omega Diagnostics has secured a Scottish Enterprise research and development grant of £1.8m. This represented a significant contribution towards the total R&D project costs to fund the planned expansion of the Company's Allersys range of reagents for use in allergy in vitro diagnostics. The project funding will be used to accelerate a growth in menu from 41 allergens to 120 allergens over the next three years to cope with anticipated increasing demand.

Full Story

28th Jul 2016

Epidarex Capital Creates Nodthera Limited

Epidarex Capital Creates Nodthera Limited

Full Story

27th Jul 2016

GSK Announces Significant New Investment in UK Manufacturing Network

 

Full Story

20th Jun 2016

NovaBiotics Announces New Data on Cysteamine (Nylexa™)

 

Full Story

16th Jun 2016

Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements

BERKELEY HEIGHTS, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today that it received notification from the Listing Qualifications Staff of NASDAQ that it has regained compliance with the minimum bid price rule for continued listing on The NASDAQ Capital Market. The notification stated that as of June 14, 2016, the Company has evidenced a closing per share bid price of its common stock in excess of NASDAQ's $1.00 minimum closing bid price requirement for at least ten consecutive trading days. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5550(a)(2) and will continue to trade on The NASDAQ Capital Market.

Full Story

14th Jun 2016

SLA Response to SFC Innovation Centre Consultation

The SLA exists to represent and promote the interests of the life sciences sector in Scotland. Scottish Government / SFC policies aimed at encouraging the sector’s competitiveness by enabling universities to help drive economic growth, and through better access to university research by businesses are issues of very great interest to our member companies, and so we are glad to have this opportunity to state our views on the important questions raised by this SFC consultation exercise. Click here to read in full the SLA response to the SFC Consultation on Innovation Centres

Full Story

7th Jun 2016

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance

Full Story

31st May 2016

Ryboquin raises £1.3m for cancer drug development

From BBC Scotland:

Full Story

27th May 2016

Aridhia Announces Expansion Following Six-Sigure Netherlands Contract

Click here for full article from Herald Scotland

Full Story

19th May 2016

ProStrakan rebrands as Kyowa Kirin

ProStrakan, the Scotland-based specialty pharmaceutical company, has rebranded as Kyowa Kirin as from the 18th April 2016.

Full Story

10th May 2016

Roslin Stem Cell Companies Combine to Create Censo Biotechnologies Group.

Roslin stem cell companies combine to create Censo Biotechnologies group.

Full Story

10th May 2016

New Funding Opportunity from Innovate UK

Businesses can apply for funding to support a range of innovation projects that tackle commercial challenges in manufacturing and materials.

Full Story

6th May 2016

Sistemic & Cynata announce cooperation on in-process purity assay development for CT product

Sistemic and Cynata announce cooperation on in-process purity assay development for Cell Therapy (CT) product. Sistemic Ltd. and Cynata Therapeutics Limited (ASX:CYP) announced today that they have entered into an agreement which will see Sistemic use its novel SistemQC™ miRNA technology platforms, together with its extensive internal databases of cellular products, to develop an in-process assessment assay for Cynata’s unique Cymerus™ Cell Therapy (CT) products. This follows an extensive period of feasibility assessment where Cynata evaluated the Sistemic technology portfolio and approach. The development of CT products represents a major breakthrough in the potential to treat a wide range of diseases which are currently untreatable. Nevertheless, the sector has many challenges, not least in terms of standardisation and scale-up. The combination of Sistemic’s predictive miRNA technology, with the standardised and highly scalable technology from Cynata, presents a potential winning combination and paves the way for rapid industrialisation of a wide range of CT products which could revolutionise the way a wide range of diseases are treated. Jim Reid, Chairman and CEO of Sistemic said “The CT industry holds much promise in so many ways for patients who have untreatable conditions, but the need for standardisation and industrialisation are big challenges the industry has not yet overcome. The combination of the technologies from two of the industry’s leading companies in trying to solve these scalability and reproducibility problems will undoubtedly enhance the speed of clinical development and subsequent uptake into clinical practice. By combining the strength of Sistemic’s technologies and understanding of the biology of cells together with the wide range of attributes of Cynata’s Cymerus technologies we see this collaboration as potentially transformational for the industry as a whole, and would represent a step change in the industrialisation of the sector.” Kilian Kelly, Vice President, Product Development at Cynata said “Cynata’s unique Cymerus technology delivers a process to manufacture a consistent therapeutic CT product. The development of robust, efficient and sensitive assays is a cornerstone of the development of such a therapeutic product, especially in view of its complex biological nature. Sistemic’s innovative SistemQC™ miRNA has a number of valuable attributes, and we expect this cooperation to help smooth the path forward for our Cymerus clinical development programs.”

Full Story

21st Apr 2016

Quotient Awarded UK’s Highest Accolade for Business Success

Leader in the development and manufacture of transfusion diagnostic products awarded prestigious Queen's Award for outstanding achievement in international trade 

Full Story

19th Apr 2016

Tissue Solutions Ltd Among the First to Transition to the New ISO 9001:2015 Standard

Tissue Solutions, a global provider of human biomaterials for research, are proud to be one of the first companies in the UK to achieve certification to the 2015 version of the ISO 9001 Management standard.  Tissue Solutions was independently assessed in January 2016, and achieved certification with no major non-conformances.  

Full Story

19th Apr 2016

Collagen Solutions Secures Merck Supply Agreement

 

Full Story

13th Apr 2016

Quotient Announces Positive MosaiQ™ Serological Disease Screening Results

Click here for full press release

Full Story

13th Apr 2016

Quotient Announces Achievement of Major MosaiQ™ Milestones & Preliminary Financial Results

• Initial Manufacturing System for MosaiQ™ Consumables Successfully Commissioned • First MosaiQ™ Field Trial Instruments Built and Received for Internal Evaluation Click here for full press release

Full Story

11th Apr 2016

Össur acquires Touch Bionics

Össur acquires Touch Bionics Apr 11th, 2016 Össur has today signed an agreement to acquire Touch Bionics Limited, a leading global provider of innovative upper limb prostheses and supporting services. Touch Bionics has over 120 employees with operations in Scotland, Germany, and the United States. In 2015, total sales amounted to GBP 15 million (USD 21 million) with an adjusted EBITDA of GBP 0.9 million (USD 1.3 million).

Full Story

24th Mar 2016

Launch of New European Stem Cell Bank

Click here for the full press release

Full Story

24th Mar 2016

Life Sciences Skills Update

Click the link to view the latest SDS newsletter

Full Story

10th Mar 2016

Scotland Launches World Class Entrepreneurship Programme - Scotland Can Do SCALE

 SCOTLAND LAUNCHES WORLD CLASS ENTREPRENEURSHIP PROGRAMME

Full Story

22nd Feb 2016

GlaxoSmithKline Irvine Penicillin Plant Creates 55 Jobs

Image copyrightSPL

Full Story

2nd Feb 2016

Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

 

Full Story

2nd Feb 2016

Lamellar Biomedical - Visco-ease Paper Published in Supportive Care Journal

Visco-ease Paper Published in Supportive Care Journal

Full Story

1st Feb 2016

Aridhia data platform used in major £64m European research collaboration to tackle Alzheimer's

Aridhia’s data platform used in major £64m European research collaboration to tackle Alzheimer’s dementia

Full Story

29th Jan 2016

My World of Work: careers web service launch

My World of Work: careers web service launch

Full Story

28th Jan 2016

Vascular Flow Technologies closes £10M financing round for strategic realignment

 

Full Story

28th Jan 2016

Roslin Cell Sciences relocates to larger premises at Roslin BioCentre

 Roslin Cell Sciences relocates to larger premises at Roslin BioCentre

Full Story

11th Jan 2016

Synpromics & CT Catapult announce joint project aimed at helping to commercialise gene therapy

  

Full Story

11th Jan 2016

Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016

 

Full Story

11th Jan 2016

Roslin Cells creates two commercially focused subsidiaries: Roslin Cell Therapies & Roslin

Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations. Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trial. Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.

Full Story

11th Dec 2015

SLA Welcomes News that Quotient is to Develop New Manufacturing Facility Near Edinburgh

Quotient Limited Announces Plans for New Product Development and Manufacturing Facility Near Edinburgh, Scotland   JERSEY, Channel Islands, December 9, 2015 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it has entered into a construction contract with MW High Tech Projects UK Limited for a new product development and manufacturing facility at the Midlothian Biocampus (the “Biocampus Site”) near Edinburgh, Scotland. The Contract provides for the first phase of the project, encompassing product manufacturing, which is expected to be completed by August 2017. The estimated cost of the first phase is approximately £15 million, or $23 million at current exchange rates, with funding expected to be provided primarily from the proceeds of a sale and leaseback transaction.   Click here for the full Press Release   

Full Story

9th Dec 2015

AGTC and Synpromics Limited Announce R&D Collaboration

AGTC and Synpromics Ltd Announce R&D Collaboration to Develop Synthetic Promoters for Enhanced Gene Therapy Candidates

Full Story

1st Dec 2015

Biopta to be acquired by Japanese stem cell company ReproCELL

The Japanese regenerative medicine company ReproCELL Inc., has announced the acquisition of the Scottish life sciences company, Biopta. The acquisition of Biopta and its US subsidiary, Biopta Inc. is expected to complete on the 10th of December and is aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services. The acquisition will also see an immediate investment to expand Biopta’s range of contract research services. Biopta, which will continue to operate from its headquarters in Glasgow, aims to grow its workforce to 30 over the next three years and Biopta’s management views the synergies within the ReproCELL Group of companies as key to its growth ambitions. Dr David Bunton, Biopta’s co-founder and CEO said, “The acquisition by ReproCELL is a great opportunity to build on the solid platform we have in outsourced drug discovery services. Scotland is known for the quality of its scientists and customer service and ReproCELL’s investment recognizes these strengths. We have had a close partnership with BioServe, another ReproCELL Group company, for the past five years, which has helped us establish a very successful US subsidiary. We see the acquisition as the natural next step in the growth of the UK and US businesses.” ReproCELL, a leader in the field of stem cells and regenerative medicine, was established in 2003 with the goal of contributing to people’s health and welfare through the development of stem cell technologies. Many of ReproCELL’s technologies were developed by the stem cell pioneers, Prof. Norio Nakatsuji from the Institute for Integrated Cell-Material Sciences, Kyoto University, and Prof. Hiromitsu Nakauchi from The Institute of Medical Sciences, The University of Tokyo. ReproCELL’s CEO, Dr Chikafumi Yokoyama said of the acquisition, “This will allow our company to increase our market share by expanding our lineup of drug discovery support products aimed at the pharmaceutical industry and accelerate the development of ReproCELL’s new products and services.”      

Full Story

19th Nov 2015

New Website for SLA Member PACLA MEDICAL

Currently, PACLA MEDICAL is working on development of an automated physiotherapy device which will be used to improve the symptoms of walking difficulty, neck and back pain, in Multiple Sclerosis (MS) and chronic back pain conditions. Click the link below to access the new company website:

Full Story

18th Nov 2015

Collagen Solutions - Appointment of Chief Business Officer

The Board of Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces the appointment of Jamal Rushdy as Chief Business Officer with immediate effect.

Full Story

16th Nov 2015

Interview with Alec McLean, Lamellar Biomedical Ltd

Mike Ward, global director of content for Informa Pharma Insights, chats with Lamellar Biomedical Ltd's CEO Dr. Alec McLean at the recent BIO-Europe partnering meeting in Munich, Germany, about the firm's R&D plans for recently raised funds and progress of Lamellar's cystic fibrosis program. Interview available at link below:

Full Story

22nd Oct 2015

Vascular Flow Technologies launches Spiral Flow™ PV Bypass Graft registry in Germany

 

Full Story

12th Oct 2015

Edgar Stewart launches dedicated recruitment service for high-growth start-ups and SMEs - Talented

 Edgar Stewart launches Scotland’s first and only dedicated recruitment service for high-growth start-ups and SMEs – Talented.

Full Story

9th Oct 2015

Roslin Cells' Retinal Pigment Epithelial (RPE) Cells Used in Clinical Trial

The First Patient In A Clinical Trial Receives Investigational Treatment For 'Wet' Age-Related Macular Degeneration (AMD) Using Retinal Pigment Epithelial (RPE) Cells Manufactured By Roslin Cells Edinburgh, Scotland, 09th October 2015

Full Story

18th Sep 2015

Latest News From Collagen Solutions

 

Full Story

30th Aug 2015

Renishaw Diagnostics' new assay could revolutionise treatment of life-threatening disease

August 2015 – for immediate release    Further information: Jim Greaves, +44 1415 577933

Full Story

29th Aug 2015

Collagen Solutions To Work On Parkinson's Disease Research Project

 Click for more information in The Scotsman article and LSE - Alliance News

Full Story

25th Aug 2015

Edgar Stewart pledges investment in Scottish recruitment start-ups

Click the link to read the Edgar Stewart Press Release

Full Story

5th Aug 2015

Point One Clinic to Open Weekly Clinic in Keith for MS Sufferers

Click on the link for the article in Banffshire Herald

Full Story

30th Jul 2015

Capusugel expands in Livingston

Capsugel is expanding the Pharmaceutical Product Development and Manufacturing Capabilities at its Edinburgh Facility.

Full Story

27th Jul 2015

Proposed acquisition of Select Pharma Laboratories by Source BioScience

Source BioScience plc (‘Source BioScience’, the ‘Company’) PROPOSED ACQUISITION OF SELECT PHARMA LABORATORIES LTD

Full Story

24th Jul 2015

Lamellar Biomedical Closes £2.3 million Investment Round

Lamellar Biomedical Closes £2.3 million Investment Round

Full Story

21st Jul 2015

MGB Biopharma commences Phase I clinical trial

MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections. For press release please click here.

Full Story

20th Jul 2015

2015 MRS Sponsored Daphne Jackson Fellowships - Call Open

Daphne Jackson Fellowships - Call Open Up to three of these unique awards are again being offered by Medical Research Scotland.

Full Story

13th Jul 2015

Collagen Results Chart Year of Significant Progress

 

Full Story

7th Jul 2015

Vascular Flow expands global patent landscape with three new patents in Japan, China and Europe

 

Full Story

24th Jun 2015

Calcivis Raises £4.5m to Drive Development of the Calcivis® Caries Activity Imaging System

 Calcivis Raises £4.5m to Drive Development of the Calcivis® Caries Activity Imaging System Through to Commercialisation

Full Story

17th Jun 2015

Vascular Flow announces collaboration with Society for Vascular Surgery® PSO

 

Full Story

12th Jun 2015

NovaBiotics' Cystic Fibrosis Treatment Lynovex - Clinical Trial Data Presented

 

Full Story

9th Jun 2015

SLA Members NovaBiotics, MGB Biopharma and Lamellar join in BEAM Alliance Launch

LAUNCH OF THE BEAM ALLIANCE – EUROPES’ COMBINED ACTION AGAINST ANTIMICROBIAL RESISTANCE

Full Story

19th May 2015

Innovate UK Life Sciences Competitions - Register & Apply now

Click on the links for further information and registration details regarding the two Innovate UK competitions which have just opened:

Full Story

19th May 2015

Sistemic announces expansion of patent portfolio covering stem cell characterisation technologies

 Glasgow, UK, Sistemic Limited (Sistemic), the miRNA profiling company with headquarters in Glasgow, Scotland, announced today the expansion of its granted patent portfolio in both the European Union and in the USA.

Full Story

15th May 2015

MGB welcomes O'Neill Report findings on antibiotics

Glasgow, Scotland, 15th May 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of  anti-infectives, endorses the latest report from Jim O’Neill’s Review on Antimicrobial Resistance and welcomes the idea of a global AMR Innovation fund.

Full Story

13th May 2015

Medical Research Scotland STV News Bulletin

 news.stv.tv/video/4234003001001/

Full Story

5th May 2015

HRA announces 11 May as start date for phased roll out of HRA Approval

HRA announces 11 May as start date for phased roll out of HRA Approval

Full Story

16th Apr 2015

Clyde Biosciences Announces £2m 'Series A' Investment

A UNIVERSITY of Glasgow spin-out behind pioneering technology to evaluate drug toxicity and improve patient safety has been boosted by a £2 million investment.

Full Story

16th Apr 2015

Vascular Flow Technologies Spiral Flow™ AV Graft Improvement in Patency

 

Full Story

7th Apr 2015

BioDundee Conference Speakers Announced

Speakers Announced 

Full Story

16th Mar 2015

Sistemic announce the initiation of ground breaking exosome research in Cell Therapy

Sistemic announce the initiation of ground breaking exosome research in Cell Therapy following grant award by Scottish Enterprise

Full Story

10th Mar 2015

Craneware Partnership with Aridhia Informatics is Announced

Click on the link for Scotsman Article - Craneware inks Aridhia tie-up as profits rise 10%

Full Story

4th Mar 2015

Vascular Flow Technologies signs deal with Vascutek to strengthen presence in Europe

 

Full Story

4th Feb 2015

Vascular Flow Technologies announces appointment of Dr Barbara Bunger as Chief Clinical Officer

 

Full Story

29th Jan 2015

MRS Funding for MS Study into Physiotherapy Technique

SCIENTISTS have been granted funding to evaluate the the benefits of an innovative physiotherapy technique for treating multiple sclerosis sufferers.

Full Story

20th Jan 2015

Vascular Flow Technologies announces new Haemodialysis Access study funded by SE Grant

 

Full Story

19th Jan 2015

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management

 

Full Story

14th Jan 2015

Life Sciences Scotsman Conference Discount for SLA Members

 Life Sciences in Scotland: Realising the Manufacturing Potential

Full Story

8th Jan 2015

New Board at Edgar Stewart Selection Aiming to Support Growth in Technology SMEs

 Click on the link to read full Press Release - Edgar Stewart New Board Appointments January 2015

Full Story

6th Jan 2015

Collagen Solutions to supply collagen powder to Globus Medical Inc

Collagen Solutions to supply collagen powder to Globus Medical Inc

Full Story

24th Dec 2014

Collagen Solutions Signs Soluble Collagen Deal with Desu Medical

Click here for link to Herald Article 23 12 14

Full Story

16th Dec 2014

Collagen Solutions Signs Wound Management Deal With Kyeron Medical

Collagen Solutions Press Release -  Link to Herald Article

Full Story

1st Dec 2014

NuCana appoints Dr. Paolo Paoletti to its Board of Directors

 Link to Press Release  - NuCana Board Appointment of Paolo Paoletti

Full Story

24th Nov 2014

Vascular Flow Technologies data presented at VEITH Symposium

Data presented by Vascular Flow Technologies at VEITH Symposium shows 30% increase in one-year success rates for vascular bypass surgery, and dramatic reduction in amputations. Link to full press release here

Full Story

21st Nov 2014

Collagen Solutions plc to acquire Southern Lights Biomaterials

Liink to Collagen Solutions announcement regarding intended Acquistion of Southern Lights

Full Story

17th Nov 2014

SLA Welcomes Daily Record Article on MS Sufferer's Positive Experience of Point One Clinic

Link to Daily Record Article describing Aileen McAusland's experience of Point One Clinic

Full Story

13th Nov 2014

Royal College of Paediatrics and Child Health endorses Sitekit eRedbook

Great news from SLA member Sitekit Solutions - after three years of intense development and testing, its eRedbook has this week received the clinical endorsement required for it to be offered to the NHS market in England. 

Full Story

11th Nov 2014

SLA Evidence to Scottish Government on Uni/Business Issues

 SLA evidence to LiSAB hearing on university/ndustry issues 

Full Story

29th Oct 2014

ARIDHIA JOINS THE GLOBAL ALLIANCE FOR GENOMICS AND HEALTH

Link to Aridhia Press Release

Full Story

16th Oct 2014

Carnegie Trust: Collaborative Research Grants Call for Proposals

The Carnegie Trust for the Universities of Scotland invites applications for innovative research projects under its Collaborative Research Grants scheme. Proposed projects must:

Full Story

8th Oct 2014

Sistemic & TC BioPharm Announce Collaboration to Develop Cancer-Specific Theranostic Products

Link to press release: TC BioPharm & Sistemic cancer biomarkers

Full Story

7th Oct 2014

NovaBiotics’ Dr Deborah O’Neil Named EY UK Health Products & Services Entrepreneur of 2014

 Link to NovaBiotics Press Release

Full Story

7th Oct 2014

Company Placements Wanted for Star Students

What is the Life Science Employability Programme? Further information available here

Full Story

30th Sep 2014

Optos in £1.1 million collaboration with NHS Greater Glasgow and Clyde

Major funding announced to develop new technology to detect sight threatening disease

Full Story

26th Sep 2014

Tissue Solutions Receives Queen’s Award for Enterprise

Link to Press Release - Tissue Solutions Receives Queen's Award for Enterprise 

Full Story

22nd Sep 2014

Merck KGaA to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry

Link to Merck and Sigma-Aldrich press release

Full Story

17th Sep 2014

MGB Biopharma Secures £4m to Advance Novel Lead Antibacterial into Clinical Development

Link to MGB Biopharma Press Release

Full Story

16th Sep 2014

NovaBiotics Receives Orphan Drug Status from FDA for Lynovex® for Treatment of Cystic Fibrosis

 Link to NovaBiotics Press Release

Full Story

8th Sep 2014

Harvard University Receives Transformational Gift From Chan Family

Harvard University Receives Transformational Gift for the School of Public Health

Full Story

28th Aug 2014

Patheon Parent Company, DPx Holdings, Acquires Gallus BioPharmaceuticals

Link to News Article

Full Story

27th Aug 2014

Sunday Herald - Is there life in our science industry?

Link to Sunday Hearld Article on Life Sciences in Scotland

Full Story

28th Jul 2014

Gael team up with Compliance Path to offer complete validation service

Compliance Path partnership - press release 

Full Story

28th Jul 2014

Axis-Shield announces launch of new HbA1c assay

Link to Axis-Shield E-Newsletter

Full Story

22nd Jul 2014

SLA welcomes the UK Government investment in Scottish life sciences

Scott Johnstone, Chief Executive of the Scottish Lifesciences Association, welcomed the announcement made by the Chancellor today of UK Government investment in Scottish life sciences. He said:-

Full Story

11th Jul 2014

Prostrakan Announces Acquisition of Archimedes

Scott Johnstone, Chief Executive of the Scvottish Lifesciences Association, said "We welcome today's news that Borders-based ProStrakan has agreed to acquire Archimedes Pharma.  This is further evidence of Scotland's ability to develop globally successful life sciences businesses, and of the growing importance of this vibrant sector to the Scottish economy.  The track record of Scottish life sciences companies developing and offering innovative products and therapies speaks for itself, and we congratulate ProStrakan – and Archimedes – on this deal." 

Full Story

25th Jun 2014

BioOutsource Plans to open a US Lab Facility in Massachusetts in 2015

Business growth - US expansion Press release

Full Story

23rd Jun 2014

NovaBiotics’ Dr Deborah O’Neil Named EY Scotland Entrepreneur of 2014

NovaBiotics’ and SLA Board Member Dr Deborah O’Neil has been named EY Scotland Entrepreneur of 2014. Click here for the press release

Full Story

9th Jun 2014

Congratulation to MGB Pharma on TSB Success

SLA welcomes MGB Pharma's recent TSB award.

Full Story

5th Jun 2014

NHS Launches Health & Social Care Innovation Fund

Click here for the NHS Press Release

Full Story

2nd Jun 2014

NuCana's Acelarin Achieves High Disease Control Rate in Patients with Advanced Cancer

www.nucanabiomed.com/downloads/NuCanaASCO2014.pdf 

Full Story

29th May 2014

Epidarex Capital Raises Fund to Make Significant Investments in Early-stage UK Life Sciences

Follow the link to the Epidarex website Epidarex Capital, a leading international venture capital firm, has raised over £47.5 million to lead investments in early-stage life science and health technology companies, including spin-outs from leading research universities.

Full Story

26th May 2014

3 Places Left on Records Management Training Programme. 10% Discount!

Russell Joyce & Eldin Rammell have created a records management training programme designed specifically for records managers, archivists, document administrators and related roles in the Life Sciences sector aimed at those who have limited experience in the field, for example new staff working in a GLP archive or as a TMF administrator. We shall be delivering the first module in that programme “Introduction to Records Management and Archiving” on Thursday 12th June 2014.

Full Story

19th May 2014

Professor Robert Brown joins Collagen Solutions as Scientific Adviser

Click on the link for the full press release on Collagen Solutions website: www.collagensolutions.com/content/investors/2014/190514.asp

Full Story

19th May 2014

Intention to Float BBI Diagnostics Group

Link to Press Release

Full Story

15th May 2014

Collagen Solutions - Excellagen® Enters New Clinical Trial

 

Full Story

1st May 2014

Quotient Prices Initial Public Offering

Link to Press Release www.quotientbd.com/news/quotient-limited-prices-initial-public-offering 

Full Story

1st May 2014

Global Exposure for Touch Bionics

userfiles/140501 - UKTI Touch Bionics OMIS case study.pdf

Full Story

21st Apr 2014

Tissue Solutions Wins Queen's Award for International Trade

Tissue Solutions press release

Full Story

10th Apr 2014

SLA Welcomes Scotland's largest private investment into Nucana

The SLA is delighted to see this, the largest single private investment in a Lifesciences company in Scotland ever. It is a testament to Hugh and his team at Nucana and proves that a Scottish based company can raise substantial funds, internationally, in a key sector of the Scottish economy.

Full Story

7th Apr 2014

SDS Funded Lab Skills Course to be Delivered by Edinburgh Napier

 Life Science Opportunities 

Full Story

27th Mar 2014

Tissue Solutions Announces Appointment of Morag McFarlane as CEO

Click here for Tissue Solutions press release

Full Story

24th Mar 2014

Introducing DPx Holdings B.V.

SLA member, Patheon, is one of three business units to make up DPx Holdings B.V. which was formed as part of a $2.6 billion transaction between JLL Partners and Royal DSM in March 2014. Click below for more information, and a video link:

Full Story

24th Mar 2014

BioOutsource Launches Flagship Reverse Signalling Apoptosis Bioassay

BioOutsource - Reverse Apoptosis Bioassay Press Release and Webinar

Full Story

21st Mar 2014

2014 Regenerative Medicine + Cell Therapy competition

The Technology Strategy Board Regenerative Medicines and Cell Therapies competition went live last week.

Full Story

17th Mar 2014

Biomedical Catalyst Competition - Registration closes: 28 May 2014

 Register and apply for Biomedical Catalyst Competition

Full Story

17th Mar 2014

Competition for Single-Company and Collaborative R&D Funding June 2014

The call document for "Advancing Regenerative Medicines and Cell Therapies COMPETITION FOR SINGLE-COMPANY AND COLLABORATIVE R&D FUNDING JUNE 2014" is now available for download here

Full Story

13th Mar 2014

Growth and Investment for Leading Entrust Clinical Team

Entrust Clinical Press Release

Full Story

13th Mar 2014

New Improved TalentScotland website now live

The new, improved TalentScotland is now live, see www.talentscotland.com and the life sciences proposition is at http://www.talentscotland.com/science

Full Story

13th Mar 2014

Scottish Patent Court under planned Unified Patent Court System

Litigation actions under the forthcoming Unitary EU Patent could be raised before the Scottish Courts following an amendment to the Intellectual Property Bill as it underwent its third reading before the Westminster Parliament.  The changes to the Bill serve to include The Court of Session in Edinburgh as one of 4 possible UK Divisional Courts in which the forthcoming Unitary EU Patents could be litigated.  The changes to the Bill will be enacted provided that suitable demand for such a forum can be shown.  The inclusion of the Court of Session resulted from lobbying led by the Law Society for Scotland and Scottish MPs, both of which welcomed the amendment on the grounds that it provides greater choice to Scottish businesses.

Full Story

10th Mar 2014

Derwentside Environmental take lab space at BioCity Scotland

BioCity Press Release

Full Story

18th Feb 2014

A Global Leader in ADC Characterisation, BioOutsource, Partners With Glythera

 BioOutsource - Glythera Partnership press release

Full Story

7th Feb 2014

Epidarex Capital Leads New Investment in Edinburgh Molecular Imaging, a Pioneering Imaging Start-Up

Epidarex Capital press release 

Full Story

6th Feb 2014

MODE receives CE mark for home bowel-screening test and completes significant financing round

MODE Diagnostics Ltd Receives approval to commence sales of its digital home-use bowel-screening test; successfully completes significant financing round

Full Story

5th Feb 2014

Roslin Cells launches the first Research Grade iPS cell bank

SLA welcomes the launch of the EBiSC project which will establish a central repository for research grade iPS cells in Europe. This is a collaboration of 26 partners with a headline value of €35 million and has been a major focus for Roslin Cells since late 2012.

Full Story

5th Feb 2014

BioOutsource To Open New Biosimilar Centre of Excellence in Glasgow as Global Demand Surges

Link to BioOutsource press release 

Full Story

3rd Feb 2014

Rock Spring Is Now Epidarex Capital

                                                       ROCK SPRING VENTURES,

Full Story

21st Jan 2014

Touch Bionics Reports Surge In Sales

Link to BBC News Article on 23% revenue growth achieved by Touch Bionics

Full Story

17th Dec 2013

Encap Drug Delivery Announces Collaboration With Lipocine Inc.

Encap Lipocine Press Release

Full Story

17th Dec 2013

Angel’s fall fuels biotech’s return to market

Scotsman Article on Collbio and the takeover of Collagen Solutions

Full Story

11th Dec 2013

£3m Dementia Consortium unites MRC Technology with Alzheimer's Research UK

 £3m Dementia Consortium launched to boost dementia drug discovery

Full Story

10th Dec 2013

Healthcare Investment Opportunities acquisition of Collbio, Change of name to Collagen Solutions

Proposed Acquisition of Collbio Limited 

Full Story

9th Dec 2013

Tissue Solutions Pass Assessment Audit For ISO 9001 With BSI

 Tissue Solutions is pleased to have passed their annual continual assessment audit for ISO 9001 with BSI on the 5th December 2013, demonstrating a commitment to continually improving our quality and management systems.

Full Story

27th Nov 2013

UWI named Most Innovative Business at WeDO awards

 WeDO Awards Celebrate Scotland's Entrepreneurs

Full Story

5th Nov 2013

Irvine an opportunity as Scotland bids to grow life sciences

Irvine an opportunity as Scotland bids to grow life sciences

Full Story

23rd Oct 2013

European Approval of Ferring’s Removable Misoprostol Vaginal Delivery System, MISODEL

 European Approval of  Ferring's Removable Mioprostol Vaginal Delivery Syste - MISODEL

Full Story

21st Oct 2013

Scotland demonstrates its collaborative approach to cell therapy development

Collaborations with Roslin Cells and QCMD set to give Sistemic lead in cell characterisation standardisation and make Scotland key destination for cell therapy clinical trials

Full Story

21st Oct 2013

Sistemic and QCMD announce innovative collaboration in cell therapy field

Sistemic Ltd and QCMD Ltd (Quality Control for Molecular Diagnostics) announced today that the companies had entered into a cross-licensing agreement. The arrangement centres on Sistemic’s SistemQC™ technology which is widely used by companies developing cell-based therapies allowing characterisation of the cell products and development of potency assays for product release and QCMD’s proprietary informatics platform and characterised quality assurance materials.

Full Story

9th Oct 2013

Swinney Welcomes Life Sciences Growth and Praises New Business/NHS Partnership

Health Innovation Partnership News Release - 9 October 2013

Full Story

3rd Oct 2013

Dow AgroSciences and Synpromics Announce R&D Collaboration

Synpromics Agreement News Release

Full Story

25th Sep 2013

Onorach Unveils China Plans

Click on the link to find out more:  us2.campaign-archive2.com/ 

Full Story

19th Sep 2013

Cell Therapy Catapult & Roslin Cells to create clinical grade stem cells to accelerate research

 Cell Therapy Catapult and Roslin Cells Press Release

Full Story

28th Aug 2013

Onorach Introduce Clinical Trial Supplies

Onorach Introduce Clinical Trial Supplies

Full Story

28th Aug 2013

NovaBiotics Enters into Agreement with Taro

NovaBiotics Taro License Agreement

Full Story

27th Aug 2013

Aridhia and Peter MacCallum Cancer Centre collaborating on patient monitoring solution

Cancer Patient Monitoring -AridhiaPressRelease

Full Story

25th Jul 2013

SLA Welcomes News Of £600k Further Funding Round For MGB Biopharma

Click on the link to read more about the £600,000 investment round completed by MGB Biopharma Ltd, the Glasgow based biotechnology company working on a new class of antibacterials: http://www.mgb-biopharma.com/news.html

Full Story

18th Jul 2013

Lamellar Biomedical gains ISO 13485:2003 certification

Lamellar Biomedical was pleased to achieve ISO 13485:2003 accreditation. Great news to secure this in such a short time.

Full Story

17th Jul 2013

Tissue Solutions New Client Services Team

Tissue Solutions New Client Services Team

Full Story

4th Jul 2013

Smart Idea Store Launches Business Networking website for Innovation

A Scottish start-up company are looking for innovative lifesciences companies, investors ( business angels and VC firms) and project partners to participate in a free 3 month pilot of their website Smart Idea Store.

Full Story

24th Jun 2013

SLA welcomes greater certainty provided by US Supreme Court decision

Gordon Stark, Chair of the SLA's Innovation SIG and COO with Murgitroyd and Co, said that the long awaited decision on the patentability of gene sequencing has now been taken. Click on the link to read more: http://bit.ly/141AKcN

Full Story

17th Jun 2013

Tissue Solutions appoint new Business Development Director

Tissue Solutions Strengthen their Business Development Team

Full Story

11th Jun 2013

Moredun Makes Major Breakthrough in the War Against Worms

Scientists at the world renowned Moredun Research Institute in Scotland, have made a major breakthrough in the battle to prevent and control parasitic worm infections by successfully protecting sheep using vaccination. The team at Moredun have recently had their results published in the leading scientific journal Vaccine1 and the paper reports the most successful attempt yet to protect animals against worms, using a laboratory produced vaccine, giving hope for a sustainable control strategy that does not rely on drugs.

Full Story

10th Jun 2013

The SLA welcomes the news that Collbio Ltd has raised £250K to further develop collagen sales

Collbio, a new company set up in March this year by leading life science financiers Diagnostic Capital Ltd, together with former senior management team members Stewart White and Ross Andrews is pleased to announce the completion of an initial fundraising in excess of £250,000 from a number of private investors.  The new funds will primarily be used for working capital to enable the business to generate revenue via the provision of collagen raw materials and contract manufacturing services.

Full Story

6th Jun 2013

Fios Genomics Secures Second Funding Round

Fios Genomics Investment_Press Release

Full Story

4th Jun 2013

Encouraging results from the ProGem1 study of NUC-1031 presented at ASCO 2013

http://www.nucanabiomed.com/downloads/ASCO2013.pdf

Full Story

3rd Jun 2013

Deadline for Medical Research Scotland PhDs Announced

The closing date of Monday 15th July 2013 at 12 noon has been announced for all applications for up to 10 Medical Research Scotland PhD Studentship Awards. Click on the following link for more information, and to download all the documents needed to make an application:  http://www.medicalresearchscotland.org.uk/apply.htm

Full Story

7th May 2013

Aridhia and Life Technologies announced as lead commercial partners in SMS-IC

PressRelease_Stratified Medicine Scotland Innovation Centre

Full Story

6th May 2013

Moredun and Fish Vet Group working together to develop novel vaccines for Aquaculture

 Moredun and Fish Vet Group working together to develop novel vaccines for Aquaculture

Full Story

6th May 2013

Aridhia - Strategic partnership signals new age of stratified medicine

AridhiaPressRelease

Full Story

26th Apr 2013

BioCity CEO to deliver key address at BioScotland on 30th April

  

Full Story

23rd Apr 2013

BioOutsource opens new facility in Cambridge, Massachusetts

 Link to the press release

Full Story

17th Apr 2013

Moredun Collaborate on EU Project to Improve Safety of Drinking Water

Moredun Press Release

Full Story

15th Apr 2013

Touch Bionics i-limb controlled by new mobile app

 http://www.bbc.co.uk/news/uk-scotland-scotland-business-22116083

Full Story

18th Mar 2013

Colbio purchases assets of Angel Biomedical and secures major contract

 Collbio Limited purchases assets of Angel Biomedical and secures major contract

Full Story

14th Mar 2013

Sistemic and Progenitor Cell Therapy initiate study on stem cell characterisation technology

Sistemic and PCT press release

Full Story

4th Mar 2013

SLA welcomes the acquisition of Encap Drug Delivery by Capsugel

Capsugel Announces Acquisition of Encap Drug Delivery 

Full Story

28th Feb 2013

Alba Bioscience Raises $5 Million of Growth Finance

Additional Quotient Biodiagnostics/Alba Bioscience Fundraising

Full Story

11th Feb 2013

Anacail bringing to market new product which taps plasma power to protect products & people

Anacail news release

Full Story

7th Feb 2013

BioCity Scotland set to be the UK centre for major new drug discovery initiative

 IMI Announcement

Full Story

6th Feb 2013

SLA welcomes Government data showing strong growth in Scottish life sciences employment

 SLA News Release welcoming Scottish Government data on life sciences employment growth 

Full Story

28th Jan 2013

Win tickets and assistance to attend BIO 2013

 Please click on the link to find out about UKTI's offer of a Partnering Pass to the 2013 Bio International Convention (22nd - 25th April, Chicago)  and assistance with accomodation and flight costs: UKTI BIO Innovation Flyer

Full Story

24th Jan 2013

Achieving compliance to ISO 13485 - Barriers to success & overcoming them

 Achieving compliance to ISO 13485 - Barriers to success & overcoming them

Full Story

22nd Jan 2013

SLA welcomes Rock Spring Ventures £50m venture capital fund

RSV press release

Full Story

10th Jan 2013

Cutting-edge technologies now searchable via _connect

Pipeline announcement

Full Story

8th Jan 2013

Scottish company Lamellar Biomedical raises £3.3 million from Institutional investors

  Edinburgh, 7 January 2013:  Lamellar Biomedical is pleased to announce that it has raised £3.3  million in equity financing from existing and new shareholders including Barwell, Scottish Enterprise  and TRI Cap angel investors. Funds managed by Invesco Perpetual form the core of the new  shareholding.  The proceeds of the offering will be used to further develop the Company’s lead product, LMS-611.  The company has been advised by a Notified Body that LMS-611 will be regulated as a class 2b  medical device for the treatment of dry eye disease (DED) and Radiotherapy Induced Xerostomia  (RIX), commonly known as dry mouth. Lamellar Biomedical has been successful in forging strong  links with the Scottish clinical community and is pleased to be working with the Vision Sciences Unit  at Glasgow Caledonian University and the Beatson West of Scotland Cancer Centre respectively in  these development programs.  Additionally Lamellar Biomedical is progressing with a clinical program to investigate the role of  LMS-611 as a medicinal product in cystic fibrosis. This program is being led by the West of Scotland  Cystic Fibrosis unit led by Dr Steve Bicknell and Dr Gordon MacGregor.  On the research front Lamellar has been successful in applying for three PhD studentships which will  be held at the Roslin Institute and the Universities of Glasgow and Strathclyde.  Following the completion of the financing Dr Duncan Moore has been elected as Chairman of the  Company. Duncan Moore is a Partner at East West Capital Partners and was previously Global Head  of healthcare equity research at Morgan Stanley. About Lamellar Lamellar Biomedical Ltd was established in June 2007 when the founding Directors of the Company,  recognising the considerable therapeutic potential of Lamellasomes™, acquired the intellectual  property rights to the technology. The Company benefits from an entrepreneurial Board of Directors and Management Team, a Scientific  Advisory Board of eminent scientists and a Research Team with intimate knowledge of lamellar body  physiology and pathology.   Contacts: Dr Alec McLean CEO Tel:   +441698748832 Dr Duncan Moore Chairman Tel; +447785971715

Full Story

8th Jan 2013

Proposed Merger of Equals between Vivalis and Intercell

 

Full Story

20th Dec 2012

Alba Bioscience streamlines and improves their compliance processes with Gael

Alba Bioscience announcement

Full Story

20th Dec 2012

Quantics and YHEC team up to offer Indirect and Mixed Treatment Comparisons

YHEC and Quantics

Full Story

18th Dec 2012

FUNDING FOR COLLABORATIVE R&D – GO FOR IT! Aquapharm’s success in getting funding for collaborat

 Aquapharm is a small but innovative Scottish life sciences discovery company pioneering the development of breakthrough products founded on the vast, untapped chemical diversity of marine micro-organisms.  The company's goal is to harness this novel resource to rapidly discover and develop novel pharmaceuticals able to target unmet clinical needs in oncology and multi-drug resistant bacterial infections. 

Full Story

30th Nov 2012

Omega Diagnostics Group PLC - Regional Selective Assistance - Grant funding

Omega, the AIM listed medical diagnostics company focussed on allergy, food intolerance and infectious disease, announces that it has been awarded a Regional Selective Assistance ("RSA") grant of up to £150,000 from Scottish Enterprise.

Full Story

20th Nov 2012

National Blood Centre

 

Full Story

13th Nov 2012

EMD Millipore and Sistemic Collaborate to Identify Control Markers for Stem Cell Production.

EMD Millipore and Sistemic partnership

Full Story

6th Nov 2012

Ferring’s European Marketing Authorisation Application accepted for review.

Saint Prex, Switzerland - November 5, 2012 – Ferring Pharmaceuticals announced today that it has received confirmation from European health authorities that the Marketing Authorisation Application (MAA) for its controlled release, removable misoprostol vaginal delivery system (MVDS) has been accepted for review under the decentralised procedure. Ferring is seeking approval for the MVDS for induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated.

Full Story

6th Nov 2012

Premier Research International will manage their compliance activities using Gael's quality manageme

 Press Release

Full Story

5th Nov 2012

CYCLACEL RECEIVES $1.9 MILLION BIOMEDICAL CATALYST MEDICINE GRANT

Press release

Full Story

5th Nov 2012

TPP Global Development Ltd enters into a collaboration agreement with Sprint Biosciences AB

Download Press Release

Full Story

17th Oct 2012

Charles River Laboratories Enters Strategic Partnership with AstraZeneca

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has been selected by AstraZeneca (NYSE: AZN) as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

Full Story

10th Oct 2012

IMSL to Build Production Facility Thanks to Regional Selective Assistance (RSA)

 3rd October 2012

Full Story

10th Oct 2012

Encap Drug Delivery establishes Hot Melt Extrusion (HME) capability

 Livingston, United Kingdom, 8th October 2012

Full Story

9th Oct 2012

UWI Label - Scots Entrepreneur Celebrates New Investments

 Scots Entrepreneur Celebrates New Investments

Full Story

13th Sep 2012

MGB PRESENTED POSTER AT 52nd ICAAC, SAN FRANCISCO, September 11th 2012

 "Disposition of MGB-BP-3, a New Class of Antibacterial Agent, After Oral Administration in a Hamster Model of Severe Clostridium difficile Associated Diarrhoea (CDAD)"

Full Story

12th Sep 2012

SLA welcomes appointment of Chairman of UK Cell Therapy catapult

The Scottish Lifesciences Association (SLA) welcomes today's appointment of its Chairman, Dr John Brown CBE FRSE to the role of Chairman at the UK Cell Therapy Catapult. The appointment has been made by the Technology Strategy Board, which is setting up a series of Catapults across the UK for advanced technology sectors.

Full Story

4th Sep 2012

Tissue Solutions Moves to the West of Scotland Science Park

 Tissue Solutions Ltd has moved to a new suite of offices at the West of Scotland Science Park having outgrown its current premises in Clydebank.   Founded in 2007 as a provider of ethically acquired human tissue for preclinical drug research, Tissue Solutions has grown steadily year on year gaining a strong international reputation. The company has a client profile that includes all the major pharmaceutical companies world-wide, and has distributors in Japan and Israel.

Full Story

23rd Aug 2012

SLA Member Aquapharm stars on BBC

 Talking to the BBC this morning, Aquapharm directors outlined the fascinating search for new pharmaceutical products from microorganisms in the sludge of Scotland's seabed. The company, an SLA founder member, operates out of Oban and Edinburgh and has been highly succesful over many years in securing large amounts of funding to support its world class research.

Full Story

23rd Aug 2012

SLA congratulates Roslin Cells on their recent success with TSB funding

 SLA is delighted to see Roslin Cells secure over £125 K in funding from the Biocatalyst Feasibility Competition. Roslin Cells will use this to  

Full Story

9th Aug 2012

Antibacterial Research: Aquapharm announces discovery of novel antibiotic compound

 

Full Story

1st Aug 2012

Gael webinar

 Just to let you know that SLA member Gael Ltd will be hosting a free webinar on Wed 29th August – ‘Implementing an effective electronic CAPA Management System’. 

Full Story

31st Jul 2012

Encap Announces $2M Capital Expenditure Programme

Livingston, United Kingdom, 3rd July 2012

Full Story

27th Jul 2012

Gael Ltd announced as exclusive sponsor of Edinburgh BioQuarter’s 2012 Regenerative Medicine Confere

Gael Ltd has been unveiled as exclusive sponsors of the Edinburgh BioQuarter Regenerative Medicine Conference 2012.

Full Story

11th Jul 2012

Work starts on £12.5m life sciences research hub in Dundee

By PETER RANSCOMBE Published on Wednesday 11 July 2012 00:00

Full Story

6th Jul 2012

BioCity Scotland appoints new Managing Director

Former Global Services Solutions director with GE Life Sciences, Fraser Black, has been appointed as managing director of BioCity Scotland, the centre for life science businesses. Black takes over from Ian Webster, acting managing director since the organisation’s launch in January. He brings extensive experience in the life sciences sector to his new role; he joined GE Life Sciences UK in 2005 having previously held VP positions with Amersham Bioscience in both bioscience services and sales and marketing. As president of Hoefer Pharmacia Biotech, a wholly-owned subsidiary of Amersham Biosciences, he re-engineered the company to achieve significant growth and profitability. Between 2005 - 2011 Black held positions in the Life Science Services Division as global director of Business Development, general manager Scientific Asset Services and Global Services Solutions director. At BioCity Scotland Black will oversee the population of the 23-acre site with new and fast-growing bioscience and life sciences companies. He will continue the relationship-building with corporate partners and embed further links with the North Lanarkshire community. Dr Louis Nisbet, BioCity Scotland chairman said, “We are delighted that Fraser Black will lead the next stage of development at BioCity Scotland. In Fraser we have a truly committed individual whose enthusiasm for our work is already infectious. He brings business development experience honed in the international life sciences arena, as well as world-class team-building skills so we are in very good hands.”  

Full Story

2nd Jul 2012

MODE Diagnostics attracts over £1,100,000 funding

Press Release

Full Story

22nd Jun 2012

Scottish Lifesciences Association welcomes Scottish Government announcement on Innovation in Health

Scottish Lifesciences Association welcomes Scottish Government announcement on Innovation in Health

Full Story

21st Jun 2012

Launch of Scottish-Californian stem cell research

Scottish and Californian research scientists are to work together on new medical research that could lead to major breakthroughs for people living with life-threatening conditions.

Full Story

20th Jun 2012

Sistemic Announces Customer Agreement with Cytori Therapeutics

Cytori to Utilize Sistemic’s SistemQC™ to Strengthen Understanding of Mechanisms & Support Design of Next-Generation Cell Therapies Boston, Mass., USA, June 20, 2012 / B3C newswire / – Sistemic Ltd. (“Sistemic”), a leading provider of microRNA-based problem-solving services and kit-based products, has formed a customer relationship with Cytori Therapeutics (“Cytori”). Cytori will utilize Sistemic’s proprietarySistemQC™ technology platform in its U.S. cardiac cell therapy clinical trial to molecularly characterize adipose-derived stem and regenerative cells (ADRCs). “Research has shown that within adipose tissue, as well as other cell sources like bone marrow, there are multiple distinct cell types that can contribute to efficacy,” commented Sistemic chairman and CEO Jim Reid. “Cytori selecting our SistemQC serves as another validation of our technology, particularly its flexibility to characterize a wide variety of cells for identity and potency, on a molecular level. We could not be more pleased to have reached this agreement with Cytori.” The announcement was made at the 2012 Bio International Convention in Boston, where Mr. Reid is moderating a panel on stem cell therapeutics featuring leaders from the industry, on Wednesday, June 20, at the Boston Convention Center. “SistemQC will be incorporated into our clinical development to understand which cell types within our Celution® System’s autologous heterogeneous population of ADRCs are the greatest contributors to efficacy,” said Douglas Arm, Ph.D., Senior Vice President Operations at Cytori. “With Sistemic’s novel technology, we can strengthen the mechanistic understanding of our cell output and at the same time support the design of next-generation cell therapies.”

Full Story

20th Jun 2012

$15M investment for new Inverness global R&D base

Inverness is to be the new home for all diabetes research and development into blood glucose monitoring carried out worldwide by international company LifeScan.

Full Story

24th May 2012

Roslin Institute benefits from the £250M BBSRC UK funding package

www.scotsman.com/business/technology/scots-to-benefit-from-life-sciences-250m-funding-1-2313136

Full Story

16th May 2012

Angel signs new contract with ReNeuron

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.

Full Story

10th May 2012

Angel Biomedical acquires the assets of a biomaterial and collagen manufacturing business

The Scottish Lifesciences Association wecolmes the recent acquistion by Angel Biomedical Ltd of the assets of an established biomaterial and collagen manufacturing business. Press release below:

Full Story

7th May 2012

Intercell announces EUR 25.0 million financing

Intercell announces EUR 25.0 million financing from BB Biotech and proposed private placement with selected institutional investors

Full Story

1st May 2012

McGrigors and Pinsent Masons merge

McGrigors and Pinsent Masons merge

Full Story

30th Apr 2012

The BioMedical Catalyst – Competition Open

The BioMedical Catalyst – Save the Date: Tuesday 15th May for the Scottish Information Day

Full Story

26th Apr 2012

ProStrakan’s Sancuso Approved in Europe

ProStrakan’s Sancuso Approved in Europe

Full Story

17th Apr 2012

Angel Biotechnology Holdings and TransGenRx Inc. sign £800K contract

Angel Biotechnology Holdings and TransGenRx Inc. sign contract for development of a recombinant interferon product.

Full Story

16th Apr 2012

Omega Diagnostics predicts revenue rise

For BBC link click here

Full Story

12th Apr 2012

Life sciences set to cash in on £180m funding boost

For Link to the Scotsman click here

Full Story

11th Apr 2012

Board changes at Optos

LONDON, UK, 11 April 2012 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, announces that Louisa Burdett will succeed Christine Soden as Chief Financial Officer when she steps down from this role on 31 May 2012.

Full Story

3rd Apr 2012

Innovation Centres to support business and university collaboration

To download the press release click here.

Full Story

2nd Apr 2012

MGB BioPharma ECCMID Poster Abstract Presented

Glasgow based MGB Biopharma which is developing a new class of antibiotic called DNA Minor Groove Binders, announced today that it has published the results of activity of its most advanced drug MGB-BP3 against Gram positive bacteria, including MRSA and vancomycin resistant enterococci. The company presented data at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London on April 2nd.

Full Story

2nd Apr 2012

Eden Scott partners with BioCity Scotland

Leading Scottish recruitment consultancy Eden Scott has signed a corporate partnership agreement with BioCity Scotland, the life sciences cluster in Newhouse, Lanarkshire.

Full Story

22nd Mar 2012

SLA welcomes the £100m GSK investment in Scotland

More than £100m investment confirmed for GSK manufacturing in Scotland

Full Story

15th Mar 2012

MGB Biopharma awarded TSB Proof of Concept grant

TECHNOLOGY STRATEGY BOARD GRANT AWARDED FOR PARENTERAL PROJECT

Full Story

14th Mar 2012

TSB Funding call for Stratified Medicine – Diagnostics for Adverse or Non-Response

The government is inviting UK companies to apply for funding to develop tests that will identify patients at risk of either suffering an adverse response or not responding to specific therapies.

Full Story

13th Mar 2012

SLA Chairman joins BioCity Nottingham board

Life Sciences Industry Leader, Dr John Brown, Joins BioCity Nottingham Board

Full Story

12th Mar 2012

Tissue Solutions Achieve Certification to ISO 9001

We are pleased to announce that Tissue Solutions has been awarded ISO 9001:2008 Accreditation. The award was made through BSI Management Systems (BSI), a world leader in assessing business processes against internationally recognised standards. We are delighted to achieve this accreditation as formal recognition for our commitment to quality and continuous improvement. Customer care has always been at the forefront of our business and ISO certification provides our customers with further reassurance that we always provides a quality service.

Full Story

12th Mar 2012

SLA welcomes Welsh Assembly largesse

The Scottish Lifesciences Association is pleased to see the Welsh Assembly Government putting more resources into life sciences. Such bold initiatives are to be applauded and the SLA is working ever more closely with the Scottish Government and its agencies to ensure that the level of resources being allocated to life sciences in Scotland continues to increase. In such a globally competitive industry it is important that Scotland continually reviews its offering to ensure we remain an attractive destination for the life sciences sector

Full Story

6th Mar 2012

Alba Bioscience Parent Company, Quotient Biodiagnostics, Raises $11.2 Million of Growth Finance

Quotient Biodiagnostics Raises $11.2 Million of Growth Finance Led by Galen Partners  

Full Story

5th Mar 2012

Angel Biotechnology appoints Dr. Stewart White as Acting CEO

Angel Biotechnology Holdings plc

Full Story

5th Mar 2012

Roslin Cells To Manufacture iPS Cells For Bipolar Disorder Research

Roslin Cells Ltd, announced today that it will be participating in a consortium to generate human induced pluripotent stem cells (iPS cells) to study bipolar affective disorder. The consortium led by Professor Andrew McIntosh from the University of Edinburgh is the winner of a 2011 CRACK-IT Challenge organised by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs).

Full Story

29th Feb 2012

Integrated Magnetic Systems Ltd awarded a SMART R&D grant for “Magnetic Antibodies”

Integrated Magnetic Systems Ltd (IMSL), a bio-nanotechnology company based in Dundee Scotland, announces that it has won a Scottish Enterprise SMART:Scotland R&D award to further develop their proprietary magnetic protein technology.

Full Story

29th Feb 2012

BioCity Scotland joins forces with Harrison Goddard Foote

BioCity Scotland, the newly-opened life sciences cluster in Newhouse, Lanarkshire, has signed a three-year agreement with leading patent attorneys HGF making them the first corporate partner.

Full Story

26th Feb 2012

Warning Label Wins Backing from US Business High Flier

An ingenious invention that warns when food or other products are about to expire has won backing from an influential figure in the American aviation industry.

Full Story

23rd Feb 2012

Boards 'hampered by non-executives'

For a link to the articel click here

Full Story

22nd Feb 2012

SLA members successful in Medical Research Scotland PhD programme

The SLA is delighted with recent success with the Medical Research Scotland PhD Studentship Programme. For further information please click here

Full Story

9th Feb 2012

SLA welcomes the increased investment in life sciences by the Scottish Government

Health Secretary Nicola Sturgeon announces the launch of a £600K Innovation Fund, much wecolmed by the SLA.

Full Story

9th Feb 2012

No Expiry Date on Ingenuity As UWI Technology Claims Major Award

An ingenious Scot’s invention that warns when food or other products are about to expire has claimed one of the biggest accolades in the scientific sector.

Full Story

8th Feb 2012

Sistemic to work with TiGenix on landmark rheumatoid arthritis cell therapy product

Download Press release here

Full Story

6th Feb 2012

McGrigors and Pinsent Masons to Merge

McGrigors and Pinsent Masons to Merge

Full Story

20th Jan 2012

Roslin Cellab’s Study Determines BioCision’s CoolCell® Technology to be superior

Download release

Full Story

19th Jan 2012

Alba Bioscience receives FDA license to sell additional products in the USA

Dowload press release  

Full Story

11th Jan 2012

BioCity Scotland Ltd secures former MSD research site

BioCity Scotland Ltd secures former MSD research site

Full Story

19th Dec 2011

Plant closure led to birth of firm with global ambitions - Gael Limited

Plant closure led to birth of firm with global ambitions

Full Story

18th Dec 2011

Reid plans expansion at Sistemic

www.scotsman.com/scotland-on-sunday/business/reid_plans_expansion_for_sistemic_1_2014758

Full Story

1st Dec 2011

Drs Russell Greig and Alex Chanas join BigDNA Advisory Board

Edinburgh based vaccine development company BigDNA has expanded its Advisory Board with the appointments of Dr Russell Greig and Dr Alex Chanas. Both executives each have over 30 years top-level experience in the pharmaceutical industry - Dr Greig having held senior positions at Glaxosmithkline/SR One and Dr Chanas at Pfizer Ltd.

Full Story

29th Nov 2011

NuCana BioMed Secures $10.4 Million Series A Financing

Download Press Release

Full Story

17th Nov 2011

Mather appointed Chairman of Gael Ltd

Mather appointed Chairman of Gael

Full Story

3rd Nov 2011

Michael Moore - Secretary of State for Scotland Visits Quintiles in Livingston

Michael Moore visited Quintiles as part of the SLA's engagement week. Issues discussed included how the Scotland Office can help in regulatory issues that apply to SLA member companies.

Full Story

25th Oct 2011

The SLA welcomes the New NRS Career Researcher Scheme

The Scottish Lifesciences Association has welcomed the Scottish Government's support of the NRS Career Researcher Fellowship to support the next generation of researchers in NHSScotland. Scott Johnstone, CEO of the SLA said: "This investment will enable SLA member companies to engage with the brightest new researchers in NHSScotland and we are committed to working with the R&D Directors to facilitate this"

Full Story

24th Oct 2011

The University of Edinburgh agrees a collaboration agreement with GSK

Monday 24th October 2011

Full Story

23rd Oct 2011

Gael uses iPads to keep aircraft safe

Gael uses iPads to keep aircraft safe

Full Story

20th Oct 2011

Ferring Pharmaceuticals Acquires Controlled Therapeutics

Ferring Pharmaceuticals has acquired Controlled Therapeutics in East Kilbide as part of the Group acquisition.

Full Story

18th Oct 2011

TPP Global Development enters into a collaboration agreement with the University of Dundee

TPP collaboration with the University of Dundee.

Full Story

11th Oct 2011

Omega Diagnostics in India move

Omega Diagnostics in India move Alva-based medical testing company Omega Diagnostics has set up a subsidiary in India as it looks to tap into the country's major growth potential for allergy products.

Full Story

21st Sep 2011

Sistemic supports Talent Scotland

NEWS RELEASE

Full Story

9th Sep 2011

Axis-Shield receives FDA clearance for new anti-CCP assay

Dundee, Scotland, 26 August 2011. Axis-Shield plc (LSE: ASD, OSE: ASD) ("Axis-Shield", the "Company" or the "Group"), the international and innovative in vitro diagnostics company, today announces that a new version of the Company's anti-CCP ELISA kit for the diagnosis of rheumatoid arthritis has been cleared for use by the US Food and Drug Administration ("FDA") under the 510(k) procedure. The new kit increases the assay range and contains changed components for reduced manufacturing costs and improved margins.

Full Story

8th Sep 2011

Cell characterisation experts Sistemic join the Alliance for Regenerative Medicine

NEWS RELEASE

Full Story

29th Aug 2011

Eden Scott injects fresh expertise into Life Sciences team

Leading Scottish recruitment consultancy Eden Scott has recruited Lynsay Nixon to its fast-growing Life Sciences team. She brings to the firm a wealth of industry experience and expertise gained from working with several innovative and entrepreneurial life sciences businesses, including ImmunoSolv, Quotient Bioresearch and Aptuit. 

Full Story

25th Jul 2011

SLA Scottish Life Sciences Engagement week

The SLA is mounting the first Scottish Life Sciences Engagement Week this autumn,  from 19 – 27 October.

Full Story

14th Jun 2011

Scottish healthcare technology collaboration to support personalised treatment of cancer

 

Full Story

13th Jun 2011

Dr John Brown receives CBE and Kevin Moore an OBE in Queen’s Birthday honours

Edinburgh, 13th June 2011. The Scottish Lifesciences Association is delighted to announce that its Chairman, Dr John Brown, has received a CBE. In the same honours list Kevin Moore, SLA’s newest Board member, has received an OBE.

Full Story

12th Jun 2011

BIOMEDICAL COMPANIES SET FOR CHARITY BOOST IN SCOTLAND

An innovative new funding initiative developed by Scotland’s most comprehensive medical research charity will provide a significant boost for businesses in the key life-sciences sector.

Full Story

24th May 2011

Medical testing firm Omega Diagnostics signs US deal

Alva-based medical testing company Omega Diagnostics has signed a deal covering the sale and distribution of its Food Detective kit in the US.

Full Story

20th May 2011

SLA writes to new Ministers

Edinburgh, 20th May 2011.  John Brown, as Chairman of the SLA, has written to Nicola Sturgeon congratulating her on her re-appointment as Cabinet Secretary for Health, and highlighting the SLA’s mission to sustain and grow life sciences in Scotland.  John has also written in similar terms to John Swinney as Cabinet Secretary for Finance and to the new Enterprise Minister, Fergus Ewing.   In these letters, John identified the following priorities for the SLA:-

Full Story

13th Apr 2011

SLA appoints David Harrison to the Advisory Board

Edinburgh, 13th April 2011. The Scottish Lifesciences Association has recruited a wide cross section of companies from the medical devices, diagnostics, biopharmaceutical and contract research organisations across Scotland. It is continuing to strengthen the board to enhance the Association’s support for the Scottish economy.

Full Story

6th Apr 2011

Sistemic's, SistemRNA platform selected by Redx Pharma for drug development screening

Glasgow, Scotland 6th April 2011; Fast growing Sistemic has signed a master service agreement with Redx Pharma, to provide its SistemRNA™ suite of drug development tools, to accelerate Redx Pharma’s preclinical development pipeline, of over 250new drug candidates.This comes on the back of the successful completion of a project which added significant value to one of Redx Pharma’s lead programmes whilst providing a significant cost saving. The news follows Sistemic’s announcement in February of an 82% increase in sales from the same period a year ago.

Full Story

6th Apr 2011

Medical Research Scotland announces an innovative change in funding stream

Following a strategic review of Medical Research Scotland's activities, including a detailed consideration of how our funds are best used to support young people in biomedical research in Scotland, the Trustees have decided to introduce an innovative new funding stream which will replace the traditional Project Grants. The very firm intention is to continue to support the careers of such young people, albeit by a different route.

Full Story

28th Mar 2011

SLA appoints John A Brown as Director of Policy

Edinburgh, 28th  March 2011. The Scottish Lifesciences Association is delighted to announce the appointment of John A Brown as it Director of Policy.   The Scottish Lifesciences Association has made a solid start to it operations in Scotland. Following the announcement to set up a Scottish body in November 2010, the Association has successfully recruited a cross section of companies from the medical devices, diagnostics, biopharmaceutical and contract research organisations across Scotland.

Full Story

17th Mar 2011

Grant Thornton calls upon the Government to protect R&D tax incentive schemes for all businesses

The Government must protect the incentive schemes that encourage investment in research and development “across the board”, says leading business and financial advisers Grant Thornton, and not be tempted by the findings of the Dyson report to restrict tax benefits to a specific sector or type of technology in this month’s Budget.   Grant Thornton says that R&D tax credit provides a clear and demonstrable incentive to invest in innovation, which is vital to the UK and Scottish economy. Suggestions that the Government might scale down this benefit by restricting its availability to ‘high-tech’ organisations, as put forward by Sir James Dyson, is causing concern.   Neil McInnes for Grant Thornton in Scotland goes on to say that while finance remains one of the biggest challenges for Scottish companies, R&D tax credits enable many SMEs and start-ups to maintain a sustained R&D programme.   He says:

Full Story

15th Mar 2011

New funding for telehealthcare

 

Full Story

15th Mar 2011

AXIS-SHIELD 2010 PRELIMINARY RESULTS

REVENUES EXCEED £100 MILLION & MAIDEN DIVIDEND ANNOUNCED

Full Story

3rd Feb 2011

Sistemic Sales Gain Pace in 2011

Glasgow, Scotland, February 2, 2011 / b3c newswire / - Sistemic, focussed on providing microRNA-based problem solving services and kit based products to the life sciences research and development markets, is certainly living up to its high growth expectations and award winning tag as Nexxus, Most Promising Company of the Year and has now started 2011 with a bang. This month the company has signed Master Service Agreements with RedX Pharma based in Liverpool, a subsidiary of a large pharmaceutical company in Cambridge, Massachusetts and not forgetting about their home ground, Glasgow University. The gain in the market has been driven by their solid science aligned with their focused commercial strategy which in turn has driven an 82 % increase in sales from the same month a year ago. This places Sistemic on a very firm footing from which it will further expand its efforts globally over the coming year as well as marks a significant milestone in its growth. Sistemic’s Chief Executive, Jim Reid commented that “….It has been a great start to the year and really confirms the strength and broad applicability of our technologies. Sistemic is about giving our clients more instructive information on their system from microRNA profiling, be it in drug discovery or cell QC. The Sistemic approach gives the knowledge to our clients to guide their future development or business decisions and this unique position is resulting in significant commercial interest. 2011 has started well and we expect this to continue with the company continuing to expand its patent protected portfolio of products and services, increasing its Glasgow & Boston facilities as well as expanding internationally to service its increasing global customer base”. Dr. Neil Murray of RedX Pharma commented “We have found the Sistemic approach unique and compelling and we look forward to developing a long and mutually beneficial relationship with them where they will help us with our drug discovery programmes, to bring new treatments faster, cheaper and with more chance of success to the market”. Sistemic’s primary business is focussed on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology markets and the Cell Therapy community. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells, as well as monitoring the QC of production. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™.

Full Story

27th Jan 2011

SLA Launches

The SLA is now up and running. From the 1st January 2011 the Scottish Lifesciences Industry has a new association. This group has been formed from the BIA (Scotland) but now covers medical devices and diagnostics. This new association has been welcomed by the Scottish government and industry.

Full Story

Collagen Solutions To Work On Parkinson's Disease Research Project

 Click for more information in The Scotsman article and LSE - Alliance News

Full Story